TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Endothelial Dysfunction Among Woman With Endometriosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women who undergoing surgery for removal of endometriosis implants~Exclusion Criteria:~* Women under 18 or above 60 years of age~* Women with known vascular disease~* Women with chronic disease which effect the endothelial function (Diabetes mellitus, Hypertension, Obesity (Defined as BMI≥30), Atherosclerosis, Kidney disease, Collagen disease, Chronic inflammatory disease, and Etc.~* History of Cardio-vascular event or venous thromboembolism (VTE)~* Smoking~* Pregnant women or gave birth in the past 3 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- endometriosis (Type: EXPERIMENTAL): Women who undergoing surgery for removal of endometriosis implants
- non-endometriosis (Type: ACTIVE_COMPARATOR): Women who undergoing surgery for removal of benign masses in the pelvis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of the Ethmoid Sinus Spacer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 21 years old~2. Both male and female~3. Ethmoid disease on CT scan~4. At least one non-ethmoid sinus requiring treatment~5. Failed medical management and symptomatic~Exclusion Criteria:~1. Previous ethmoid surgery~2. Not sufficient room for placement of Spacer~3. Patient requires septoplasty~4. Has received steroid treatment with in 2 weeks~5. Extensive sinonasal osteoneogenesis preventing device placement~6. Sinonasal tumors or obstructive lesions~7. History of facial trauma that distorts sinus anatomy~8. Asthmatic patients with aspirin sensitivity~9. Pregnant or lactating females

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ethmoid Sinus Spacer placement (Type: EXPERIMENTAL): Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a clinical diagnosis of RVO in the study eye~* Has a CST of ≥ 300 µm in the study eye~* Has an ETDRS BCVA score of ≥ 20 letters read and ≤ 70 letters read in the study eye;~* Is naïve to local pharmacologic treatment for RVO in the study eye;~Exclusion Criteria:~* Any active ocular disease or infection in the study eye other than RVO~* History of glaucoma, intraocular pressure \> 21 mmHg or ocular hypertension requiring more than one medication~* Any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study~* Any evidence of neovascularization in the study eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections
- Control (Type: ACTIVE_COMPARATOR): IVT aflibercept (2 mg/0.05 mL) + sham SC procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Preventing COVID-19 Complications With Low- and High-dose Anticoagulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: adult patient with COVID-19 infections, admitted to:~* an acute non-critical medical ward with admission D-dimer levels \>1,000ng/mL, or~* an acute critical ward (ICU, intermediate care unit)~Exclusion Criteria:~* ongoing or planned therapeutic anticoagulation for any other indication~* contra-indication to therapeutic anticoagulation~* hypersensitivity to heparin~* personal history of heparin-induced thrombocytopenia~* suspected or confirmed bacterial endocarditis~* bleeding events or tendency due to a suspected or confirmed hemostatic bleeding disorder~* organic lesion prone to bleeding~* platelet count \<50G/L, Hb level \<80g/L~* ongoing or recent (\<30 days) major bleeding, ischemic stroke, trauma, surgery~* use of dual antiplatelet therapy~* pregnancy~* bodyweight \<40kg or \>150kg.~* end of life care setting~* unwillingness to consent~* ongoing participation in a COVID-19 randomized clinical trial testing another therapeutic intervention

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Therapeutic anticoagulation (Type: EXPERIMENTAL): Participants will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin) or intravenous unfractionated heparin, from admission until the end of hospital stay or clinical recovery.
- Prophylactic anticoagulation (Type: ACTIVE_COMPARATOR): Participants will be treated with prophylactic doses of subcutaneous low-molecular-weight heparin (enoxaparin) or unfractionated heparin, from admission until the end of hospital stay or clinical recovery. If hospitalized in the intensive care unit, they will receive an augmented thromboprophylaxis regimen as standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Imaging Study for FdCyd and THU Cancer Treatment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Enrolled in the National Institutes of Health (NIH) Phase II Clinical protocol evaluating 5-fluro-2'-deoxycytidine (FdCyd) with Tetrahydrouridine (THU) (09-C-0214) with target lesion measured as greater than or equal to 10mm with spiral computed tomography (CT) scan.~* Written, voluntary, informed consent of the patient must be obtained in compliance with institutional, state and federal guidelines~* For females: Negative serum pregnancy test OR post-menopausal for at least 2 years OR patient has had a hysterectomy~EXCLUSION CRITERIA:~* Participants with severe claustrophobia unresponsive to oral anxiolytics~* Subjects weighing \> 400 lbs (weight limit for scanner table), or unable to fit within the imaging gantry~* Known allergy to FdCyd~* The subject is unable to lie still for 75 minutes~* 5 Pregnant or lactating women. Pregnant women are excluded from this study because the effects of 18F-FdCyd in pregnancy are not known. Because there is an unknown but potential risk for adverse events in nursing infants secondary to administration of 18F-FdCyd in the mother, breastfeeding should be discontinued if the mother receives 18F-FdCyd~* Participants with any co-existing medical or psychiatric condition that is likely to interfere with study procedures and/or results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 1/Intravenous (IV) Tetrahydrouridine (THU) (Type: EXPERIMENTAL): \[F-18\]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
- 2/Oral Tetrahydrouridine (THU) (Type: EXPERIMENTAL): \[F-18\]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Colon cancer patients with no evidence of metastasis in distant organs (i.e., TNM stage I-III), who are~* between 18 and 75 years old,~* have a body mass index (BMI) between 18 and 35 kg/m\^2,~* and are eligible for laparoscopically-assisted colectomy for primary tumor resection.~* Patients must have the ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~- A history of allergic-type reactions to celecoxib or sulphonamides,~* a history of asthma, skin reactions or other allergic reactions to aspirin or other NSAIDs,~* a history of thromboembolic event (cerebrovascular accident, transient ischemic attack,~* unstable angina, myocardial infarction, deep vein thrombosis, or pulmonary embolism),~* renal insufficiency (defined by a serum creatinine level \> 1.5 mg/dL or blood urea nitrogen level \> 22 mg/dL),~* active gastrointestinal bleeding in the 60 days before surgery,~* alcohol or drug abuse, and~* previous chemotherapy or abdominal/pelvic radiation therapy.~* After randomization, other exclusion criteria will include a surgical procedure longer than 6 h, inability to extubate the trachea within 4 h after operation, evidence of a new postoperative myocardial infarction, abnormal postoperative mental status or any new neurologic deficit, significant postoperative bleeding (with a hemoglobin level \< 7.5 g/dL), requiring blood transfusion, or a urine output of less than 30 mL/h.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Celecoxib (Type: EXPERIMENTAL): Celecoxib, 200 mg tab
- Placebo (Type: PLACEBO_COMPARATOR): placebo, tab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nutrition and Pharmacological Algorithm for Oncology Patients Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with a diagnosis of head/neck, lung, pancreatic cancer, or metastatic cancer from any solid tumor~2. Planned, ongoing, or recently treated patient (within the past 30 days) with chemotherapy, immunotherapy, and/or intravenous targeted biologic therapy~3. No previous use of appetite stimulants~4. All patients must sign study specific informed consent prior to being included in the study~5. No contraindication to appetite stimulants~Exclusion Criteria:~1. Patient \<18 years old~2. Contraindication to appetite stimulants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with fair to good appetite (Type: ACTIVE_COMPARATOR): The patients with fair-good appetite (score on CNAQ more than 24) will not receive any pharmacological agents and will receive nutrition intervention alone.~CNAQ = Council on Nutrition Appetite Questionnaire
- Patients with poor to fair appetite (Type: EXPERIMENTAL): The patients with poor-fair appetite (score on CNAQ less than 24) will be provided nutrition intervention by the Registered Dietitian and then put into one of three pharmacological groups.~CNAQ = Council on Nutrition Appetite Questionnaire

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Impact of Sleep Apnea on Cerebral Volumetry According to Age

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria for patients:~* 18-55 or more than 70 years old~* SAOS (AHI\>30) never treated before~* consent form signed~Inclusion Criteria for subjects:~* 18-55 or more than 70 years old~* No SAOS (AHI\<10)~* consent form signed~Exclusion Criteria (subjects and patients) :~* Contraindication in the practice of MRI: pacemaker, metallic cardiac valve, intra-ocular metal part~* Contraindication in the injection of Gadolinium (allergy during a previous radiological examination).~* Type 1 or 2 diabetes~* History of cerebrovascular accident, myocardial infarction, congestive heart failure~* Chronic and/or severe renal insufficiency~* Chronic respiratory failure~* Neurological pathology~* Central origin sleep apnea (AHIcentral \> 15)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Eldery SAOS+ (Type: None): Patients with severe obstructive sleep apnea (AHI\>30) 70 years old and more
- Eldery SAOS- (Type: None): People without obstructive sleep apnea (AHI\<10) 70 years old and more
- Adult SAOS+ (Type: None): Patients with severe obstructive sleep apnea (AHI\>30) 18 \< Age \< 55 years old
- Adult SAOS- (Type: None): People without obstructive sleep apnea (AHI\<10) 18 \< Age \< 55 years old

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Octaplas Adult TTP Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patient is a male or female at least 18 years of age or older.~2. Patient has a diagnosis of TTP or suspicion of TTP that is planned on being treated with TPE within 3 days of study entry.~3. Patient has thrombocytopenia (platelets \< 100 x 10P9P/L).~4. Patient is willing to give voluntary written informed consent before any study-related procedure is to be performed that is not part of standard medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.~Exclusion Criteria:~1. Patient has a history of severe hypersensitivity reaction to plasma-derived products or to FFP.~2. Patient has an already known IgA deficiency with documented antibodies against IgA.~3. Patient is currently participating in an interventional clinical study or has participated during the past 1 month prior to study inclusion.~4. Patient has severe deficiencies of Protein S.~5. Patient received more than 1 treatment of plasma exchange or plasma infusion for current episode of TTP prior to randomization.~6. Patient is currently taking ACE-inhibitors; in case patient is under ACE-inhibitor treatment a wash-out period of at least 24 hours has to elapse prior the first plasma infusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Octaplas (Type: None): Patients receiving Octaplas for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures
- standard plasma products (Type: None): Patients receiving standard plasma products (e.g., FFP, etc) for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Assessment of Next Science Solution on Gustilo and Anderson Type II and IIIA or IIIB Tibial Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female 18 to 65 years old~2. Scheduled to undergo surgery to repair open tibial fracture~3. Willing and able to comply with all study procedures and be available for the duration of the study~4. Provide signed and dated informed consent or obtain consent from legally authorized representative~5. Not be pregnant, planning to become pregnant, or nursing female subjects.~Exclusion Criteria:~1. Unable to provide signed and dated informed consent or unable to obtain consent from a legally authorized representative~2. Unable or unwilling to comply with all study-related procedures~3. Known history of allergic reaction to any of the study products or its components, including any products used for standard of care (such as dressings or any coverings)~4. Subject has known history of contraindications to general anesthesia~5. Subject with any underlying condition or state that, in the investigator's opinion, will make them too critically ill to complete 30 and/or 90 day follow ups~6. Pregnant, planning to become pregnant, or nursing female subjects.~7. Any subject positive for Covid-19 virus at time of surgical screening~8. Tibial plateau, pilon, or Gustilo-Anderson type IIIc fractures and any fracture that will require referral to another surgical service will be excluded from this study~9. Any patient who will require ongoing use of NPWT after hospital discharge will be excluded from the study.~10. Subjects have evidence of prolonged QT segment, per EKG.~11. Subjects from a vulnerable population, in accordance with 45 CFR 46 Subparts B, C, and D

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: ACTIVE_COMPARATOR): Each of the following procedures will be conducted according to general or local site Standard of Care (SoC):~* Medication administration at surgery~* Surgical irrigation and wound debridement~* Surgical fracture preparation/fixation~* Surgical closure
- Standard of Care plus Next Science (Type: EXPERIMENTAL): In addition to the SoC, the blinded product will be applied in place of saline irrigation as the wound is closed (after bone fracture preparation/fixation), depending on the randomization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Role of Glycation and Inflammation in Acute Ischemic Heart Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* hospitalization for first myocardial infarction (STEMI or NSTEMI)~* age between 18 and 80~Exclusion Criteria:~* uncompensated T2DM (HbA1c \>53mmol/mol)~* use of anti-CD20 treatment~* chronic anti-inflammatory treatment for autoimmune disease (i.e. DMARDs, high dose FANS, cortisonic drugs)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- First Ischemic Cardiac Event (Type: None): Measurement of BAFF and MGO at hospitalization (before reperfusion) and after 3 months during follow-up

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ages 18 or older.~* Clinical features of HD AND confirmatory family history of HD; OR Clinical features of HD AND CAG repeat expansion greater or equal to 36.~* Stage I or II of illness (TFC greater or equal to 7).~* Ambulatory and not requiring skilled nursing care at the time of enrollment.~* Must be capable of providing informed consent and complying with trial procedures.~* Additional inclusion criteria apply.~Exclusion Criteria:~* History of known sensitivity or intolerability to creatine monohydrate.~* Exposure to any investigational drug within 30 days of randomization (Baseline visit).~* Use of supplemental creatine at a dose greater than 10 grams within 30 days of randomization (Baseline visit).~* Screening laboratory abnormalities that in the judgment of the investigator would jeopardize safe conduct of study.~* Clinical evidence of unstable medical illness.~* Clinical evidence of unstable psychiatric illness.~* Additional exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Randomized to receive creatine monohydrate (up to 40 grams daily)
- B (Type: PLACEBO_COMPARATOR): Randomized to receive placebo (up to 40 grams daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy